Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Resources, news and special offers to support you and your professional development during this difficult time.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Download your copy of the new events calendar and see all the online workshops, conferences, RAC exams and European online workshops RAPS has planned for 2021 at a glance.
Registration is now open for RAPS Euro Convergence 2021! Attend to join peers from EU and around the world to gain insights and exchange ideas on the regions most pressing issues.
An invaluable resource for any professional engaged in designing, composing, compiling, or commenting on regulatory documentation
From self-assessments to help you identify your strengths and areas to focus on to reference books and online courses that will help you fill in the gaps in your regulatory knowledge, RAPS has the resources to help you prepare for the RAC exam.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
Posted 26 March 2014 | By Alexander Gaffney, RAC,
In recent years, much attention has been focused on the pharmaceutical industry and its use-and non-use-of the US Food and Drug Administration's (FDA) expanded access program. But how much success has it had?
That program, sometimes referred to as the "compassionate use" program, allows patients to access experimental treatments they might otherwise not be eligible to receive.
For a full explanation of the program, please see our Regulatory Explainer on the compassionate use program.
Expanded access works, in general, in one of two ways: Either a company with an experimental product creates a new clinical trial for a patient through the use of an investigational new drug application (IND), or it amends an existing clinical trial to add new types of participants through the use of a "protocol amendment."
Once a company determines which approach it wants to take, it then needs to decide on how many patients it is willing to accommodate. There are four general types of expanded access INDs and protocols:
Those four types are found within both INDs and protocols, resulting in the following matrix:
More information can be found at 21 CFR 312 Subpart I.
By some accounts, the success of the expanded access program can be measured by the amount of access it has provided over the years. So how many INDs and protocols has FDA approved as of late?
According to new data released by FDA this week, it approves quite a few each year.
Some interesting observations from the data:
And for all the flak FDA gets for its involvement as a gatekeeper in expanded access cases, it has proven remarkably willing to grant access when companies ask for it. In the last four years, it has denied a proposed IND just 24 times, and just eight times in the last three years.
It has not denied a single proposed protocol in the last four years.
FDA, it's worth noting, can only approve expanded access at the request of a company. It cannot order (though it can negotiate with or subtly pressure) a company to do so.
FDA Data on Expanded Access INDs and Protocols
Tags: 21 CFR 312, INDs, Expanded Access, Compassionate Use, Protocols, Latest News
Regulatory Focus newsletters
All the biggest regulatory news and happenings.